Pfizer (NYSE:PFE) received its first Chinese approval for obesity drug Severwin, opening access to a major new treatment ...

Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.

Amarin (NASDAQ: AMRN) is a drug company that is in a particularly precarious position. This fact is highlighted by the company's recent move to restructure its operations in an effort to cut costs.

Fosun International, a China conglomerate led by billionaire Guo Guangchang, is projecting a loss for the 12 months to December of as much as 23.5 billion yuan, or $3.4 billion, on non-cash ...

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

For the second time in less than a year, Vinay Prasad, the head of the U.S. Food and Drug Administration’s vaccines unit, is ...

Novo Nordisk A/S remains a Buy despite CagriSema setback; Eli Lilly and Company remains a Hold on valuation. Click for this ...

Meagan Johnson recently spent four days calling dozens of pharmacies around Austin, Texas, trying to fill a prescription for her son, Jack.

Paul Singer’s Toyota Campaign Tests The Limits Of Japan’s Corporate Tradition (Observer.com) Scott Bessent’s Billion-Dollar Bet: Can Shorting Oil Tame Iran Shock? Experts Warn It Can Whipsaw ...

Explore how Moderna makes money through its mRNA vaccines, government contracts, and partnerships, and how products like its COVID-19 vaccine drive revenue.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...